---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188522"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T06:58:16.833712+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Neoleukin to merge with Neurogene; Neurogene stockholders to own ~84% of combined co.

## Summary
- Neoleukin stockholders will own ~16% of combined company; Neurogene stockholders ~84% on as-converted basis.
- Concurrent ~$95M private financing from investors to close immediately before merger.
- Closing conditions include Neoleukin net cash >= $60M and Neurogene gross proceeds >= $75M from financing.
- Post-merger board of 7 directors: 5 designated by Neurogene, 2 by Neoleukin; CVRs for legacy asset proceeds.
- Support agreements from ~77% of Neurogene and ~21% of Neoleukin stockholders; 180-day lock-up on shares.

## SEC filing metadata
- accession: 0001193125-23-188522
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/0001193125-23-188522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/d506859d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188522
- JSON: https://secwatch.observer/filing/0001193125-23-188522.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188522.txt

## Key facts
- Material Agreements
  Neurogene Inc. entered into Agreement and Plan of Merger with Neoleukin Therapeutics, Inc. (effective 2023-07-17).
  - Action: entry
  - Agreement: merger
  - Counterparty: Neoleukin Therapeutics, Inc.
  - Effective: 2023-07-17
  source text: On July 17, 2023, Neoleukin Therapeutics, Inc., a Delaware corporation (“Neoleukin”), Project North Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neoleukin (“Merger Sub”), and Neurogene Inc., a Delaware corporation (“Neurogene”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/0001193125-23-188522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.